- Home
- NTRA vs FWONA Comparison
NTRA vs FWONA Comparison
Compare NTRA & FWONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- FWONA
- Stock Information
- Founded
- NTRA 2003
- FWONA 1950
- Country
- NTRA United States
- FWONA United States
- Employees
- NTRA N/A
- FWONA N/A
- Industry
- NTRA Medical Specialities
- FWONA Broadcasting
- Sector
- NTRA Health Care
- FWONA Industrials
- Exchange
- NTRA Nasdaq
- FWONA Nasdaq
- Market Cap
- NTRA 27.0B
- FWONA 21.9B
- IPO Year
- NTRA 2015
- FWONA N/A
- Fundamental
- Price
- NTRA $208.97
- FWONA $93.44
- Analyst Decision
- NTRA Strong Buy
- FWONA Strong Buy
- Analyst Count
- NTRA 18
- FWONA 2
- Target Price
- NTRA $211.44
- FWONA $106.00
- AVG Volume (30 Days)
- NTRA 1.3M
- FWONA 127.7K
- Earning Date
- NTRA 11-06-2025
- FWONA 11-05-2025
- Dividend Yield
- NTRA N/A
- FWONA N/A
- EPS Growth
- NTRA N/A
- FWONA N/A
- EPS
- NTRA N/A
- FWONA 0.85
- Revenue
- NTRA $2,116,676,000.00
- FWONA $4,033,000,000.00
- Revenue This Year
- NTRA $25.70
- FWONA $21.87
- Revenue Next Year
- NTRA $15.42
- FWONA $10.89
- P/E Ratio
- NTRA N/A
- FWONA $113.57
- Revenue Growth
- NTRA 38.17
- FWONA 8.53
- 52 Week Low
- NTRA $125.38
- FWONA $68.00
- 52 Week High
- NTRA $210.90
- FWONA $99.52
- Technical
- Relative Strength Index (RSI)
- NTRA 77.59
- FWONA 54.19
- Support Level
- NTRA $182.20
- FWONA $91.00
- Resistance Level
- NTRA $210.90
- FWONA $94.52
- Average True Range (ATR)
- NTRA 7.65
- FWONA 2.73
- MACD
- NTRA 0.76
- FWONA 0.42
- Stochastic Oscillator
- NTRA 90.74
- FWONA 69.56
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About FWONA Liberty Media Corporation Series A Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.